We could not find any results for:
Make sure your spelling is correct or try broadening your search.
Share Name | Share Symbol | Market | Type | Share ISIN | Share Description |
---|---|---|---|---|---|
Optibiotix Health Plc | LSE:OPTI | London | Ordinary Share | GB00BP0RTP38 | ORD 2P |
Price Change | % Change | Share Price | Bid Price | Offer Price | High Price | Low Price | Open Price | Shares Traded | Last Trade | |
---|---|---|---|---|---|---|---|---|---|---|
0.00 | 0.00% | 17.75 | 17.50 | 18.00 | 17.75 | 17.75 | 17.75 | 71,791 | 08:00:00 |
Industry Sector | Turnover | Profit | EPS - Basic | PE Ratio | Market Cap |
---|---|---|---|---|---|
Noncomml Resh Organizations | 457k | 2.59M | 0.0284 | 6.25 | 16.19M |
Date | Subject | Author | Discuss |
---|---|---|---|
19/1/2017 11:52 | Won't let me post the link - can anyone else post it here? | parob | |
19/1/2017 11:52 | New proactive phone interview with SOH just out! New hires 'part of a transition for Optibiotix' says CEO 11:02 19 Jan 2017 Life sciences group OptiBiotix Health plc (LON:OPTI) CEO Stephen O'Hara talks to Proactive about the company's focus for 2017 as well as the addition of Christina Wood to the board to help create new revenue streams for the company's pipeline of products. [...] | parob | |
19/1/2017 11:44 | Spot on JJ - small incremental rises allows a more orderly rise, no doubt a few will close out towards the end of the day. | elrico | |
19/1/2017 11:39 | Nestlé, Danone, and Heinz ;o) | onedayrodders | |
19/1/2017 11:36 | 3 month high! | parob | |
19/1/2017 11:13 | Love it when a plan comes together. | monkeywench1 | |
19/1/2017 11:11 | Excuse the repetition but this really is mouthwatering .. "As the owner and CEO of Confoco, a supplier of high quality food ingredients worldwide, Christina grew the business from £1m to £10m sales by obtaining strategic supplier status with multiple global corporates including Nestlé, Danone, and Heinz. During this time, she developed a network of agents and distributors across key international markets. Christina sold her company to Diana Naturals in 2013 which was subsequently acquired by Symrise AG for US$1.75 billion in 2014." Same again please Christina ;o) | onedayrodders | |
19/1/2017 11:10 | As I said at the weekend, when this thing rises it will be difficult to get any volume. | lodger | |
19/1/2017 11:07 | It really is all coming together here and not long to wait for the real push north if we are lucky. Must admit last year was a long one for OPTI but things are looking brighter now. Some good appointments, Gofigure in profit and expanding. Now we await news of demerger and MN contracts. What a pleasant position to be in. | rafboy | |
19/1/2017 10:45 | Optibiotix - another cracking hire offsets Zak Mir buy tip PUBLISHED: 19 Jan 2017 @ 07:05 The good news is that Optibiotix (LSE:OPTI) has hired another heavy hitter. Christina Wood has been appointed as Sales and Marketing Director. Christina will join the OptiBiotix Board subject to completion of the normal regulatory due diligence The CV looks impressive. Ms Wood has more than 20 years’ sales experience within the food, nutrition, and nutraceuticals industry. Optibiotix reports: As the owner and CEO of Confoco, a supplier of high quality food ingredients worldwide, Christina grew the business from £1m to £10m sales by obtaining strategic supplier status with multiple global corporates including Nestlé, Danone, and Heinz. During this time, she developed a network of agents and distributors across key international markets. Christina sold her company to Diana Naturals in 2013 which was subsequently acquired by Symrise AG for US$1.75 billion in 2014. She joined John Morley, a leading food industry supplier, in late 2014 where as Director of Sales and Marketing, she was responsible for key consumer accounts including Sainsbury’s, Waitrose, M&S and Tesco. Ends. Jolly good. We expect more news in the coming weeks on the Tata deal and also on other commercial agreements. Now for the less good news. Chartist Zak Mir has tipped the shares as a buy with a 105p short term price target. Like the broken clock we think that Mr Mir is on this occasion correct. The shares – now 70p-72p – are a buy at up to 80p with a target to sell of 100p+ likely to be achieved pretty soon. | scotty1 | |
19/1/2017 10:34 | The tide has certainly turned here. Could see 75p+ today. | someuwin | |
19/1/2017 10:26 | Can get 10,000 at 73p with my broker Although stock is tight | judijudi | |
19/1/2017 10:12 | Yes, I had trouble buying 4k shares earlier and had to pay 73p! | rafboy | |
19/1/2017 10:10 | Can't get an online buy quote for £1k | someuwin | |
19/1/2017 08:45 | Blue soon methinks.... | bernieboy | |
19/1/2017 08:24 | i make it's currently 69.65 to sell and 71.9 to buy edit, now 70.65 to sell | neftanikoff | |
19/1/2017 08:11 | Not sure why the bid has dropped. I can sell 25K online for 71.4p.Is there another large buy order being worked again? | parob | |
19/1/2017 07:22 | Barchart is now signalling an overall average of 56% buy - up from 48% buy after Friday's rise: The chart is looking good and from the posts above it sounds like Zak agrees! | parob | |
18/1/2017 22:47 | And after rising 370% (500%+ at one stage) FITB ended the day suspended 'pending an announcement'. Good news or bad? Was the whole rise a pump to get a placing away? Will be interesting to watch tomorrow. | someuwin | |
18/1/2017 22:35 | Thanks, nicktoten, and the other share of course went up 300%, not 3000% and i can't even say drink was an excuse for those 2 errors. | neftanikoff | |
18/1/2017 22:19 | Neft, its Tata who Opti are dealing with. | nicktopten | |
18/1/2017 20:10 | Big news coming here...my source in a red and white suit told me 25th December is the date. | onedayrodders | |
18/1/2017 20:09 | Jumps like FITBUG tend to leave many PI out of pocket and those riding from the low would have been praying they get something back after being suckered into previous rallies only to see a rapid retrace. It's in a very crowded space and MAY NEED money ASAP. | elrico |
It looks like you are not logged in. Click the button below to log in and keep track of your recent history.
Support: +44 (0) 203 8794 460 | support@advfn.com
By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions